GX 301

Drug Profile

GX 301

Alternative Names: Telomerase peptide cancer vaccine - Genovax

Latest Information Update: 25 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genovax
  • Developer Genovax; Mediolanum
  • Class Cancer vaccines; Peptide vaccines; Peptides; Vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Renal cancer

Most Recent Events

  • 01 Nov 2014 Phase-II clinical trials in Prostate cancer in Italy (Intradermal) (NCT02293707)
  • 03 Dec 2012 GX 301 licensed to Mediolanum Farmaceutici worldwide
  • 01 Feb 2012 Genovax completes a phase I/II trial in Prostate cancer and Renal cancer in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top